For example, memory T cells not expressing the CD45RAmarker can be used to reduce the risk of graft-versus- host disease[98, 99].The abundance of phosphatase among lymphoid and myeloidcells, as well as the high receptor level on the membrane[4], makes CD45 an extremely attractive targetfor CAR-T therapy both for hematopoietic tumors and upon the conditioning ofrecipient’s hematopoiesis preceding bone marrow transplantation. The gene discussed is PTPRC; the disease is hematopoietic and lymphoid cell neoplasm.